AI PRICE FORECAST
MCK Stock Forecast & AI Price Prediction
McKesson · Healthcare · Medical Distribution
MCK live signal snapshot
Shares of MCK were last at $1079.79, down 0.26% on the day, trading 3.7% below its 52-week high of $1121.50 and 49.2% above its 52-week low of $723.68. Our AI model's current call on MCK is BUY, with 87% confidence. The short-term averages line up bullishly, and the price is holding above its 50-day line. Its one-month projection is about $1115.96, a 3.3% move from the last price.
MCK's 14-day RSI is 70.8 — overbought territory, where short-term pullbacks or consolidation are common. The MACD indicator sits over its signal line, and the histogram reading of 5.18 shows buying pressure building. With the 50-day average at $948.42, 8.8% over the 200-day's $871.60, the longer-term trend structure remains positive.
14 Wall Street analysts covering MCK put the average price target at $1144.29 (range $965.00–$1260.00), implying 6.0% upside from the current price. The current recommendation trend leans bullish: 13 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 3 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive MCK dashboard for numbers updated throughout today's session.
About McKesson
McKesson Corporation (MCK) is a medical distribution company in the healthcare sector, headquartered in Irving, TX, United States. McKesson Corporation provides healthcare services in the United States and internationally. It has a market value of about $124.7 billion and roughly 41,600 full-time employees. With a beta of 0.28, the stock has historically moved less than the overall market.
MCK performance vs. the market
Year to date, MCK has gained 31.6%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 25.6%, 14.1 points better than the S&P 500. Its +12.3% move over the past month extends a +26.0% three-month run.
| Period | MCK | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +12.3% | +11.4% | −2.3% |
| 3 months | +26.0% | +12.2% | −2.3% |
| Year to date | +31.6% | +22.1% | +11.4% |
| 1 year | +25.6% | +28.3% | +11.5% |
McKesson financials at a glance
McKesson's most recent quarter (ended Sep 30, 2026) brought in $111.0 billion of revenue and net income of $1.2 billion (a 1.1% net margin). Revenue was up 7.6% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 27.9 on trailing earnings of $38.77 per share. Trailing free cash flow was $7.4 billion.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $111.0B | $1.2B |
| Jun 30, 2026 | $105.4B | $614M |
| Mar 31, 2026 | $96.3B | $1.7B |
| Dec 31, 2025 | $106.2B | $1.2B |
MCK vs. its peers
MCK's +31.6% this year ranks ahead of 2 of the 5 big healthcare names below. The strongest of the group this year is Merck & Co. (MRK, +39.8%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| McKesson (MCK) | $1,079.79 | +31.6% | 27.9 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| UnitedHealth Group (UNH) | $402.94 | +22.1% | 23.0 | HOLD |
MCK stock: common questions
What is the MCK stock price target?
14 Wall Street analysts put the average 12-month target at $1144.29, in a range of $965.00–$1260.00, versus a recent price of $1079.79. Stock Pulse 247's model projects about $1115.96 over the next month.
Is MCK a buy right now?
Our AI model currently rates MCK a BUY at 87% confidence. Among analysts, 13 rate it Buy or Strong Buy, 3 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has MCK stock performed this year?
Year to date, MCK has gained 31.6%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 25.6%, 14.1 points better than the S&P 500. Its +12.3% move over the past month extends a +26.0% three-month run.
What is MCK's 52-week high and low?
MCK has traded between $723.68 and $1121.50 over the past 52 weeks; at $1079.79 it is 3.7% below its 52-week high of $1121.50 and 49.2% above its 52-week low of $723.68.
What sector is MCK in, and who are its peers?
MCK is in the healthcare sector (medical distribution). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK).
How accurate is the MCK forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines MCK's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.